RCS - Feedback PLC - Feedback Joins NHS AI Procurement Framework

FeedbackAnnouncement

29/09/2021 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210929:nRSc2755Na&default-theme=true

RNS Number : 2755N  Feedback PLC  29 September 2021

 

Feedback plc

 

RNS REACH

 

Feedback appointed to national NHS AI procurement framework

 

·    The national framework addresses the Provision of Artificial
Intelligence (A.I), Imaging and Radiotherapy Equipment, Associated Products
and Diagnostic Imaging to public and private sector organisations

·      Bleepa has been awarded onto the framework as a product which can
facilitate the deployment of AI imaging tools into frontline clinical settings
through mobile devices, enabling on-the-go access to AI

·      The framework's estimated overall value of up to £360m enables
any NHS body a route to procure the Bleepa AI solution for the purpose of
developing, evaluating or clinically delivering AI imaging tools

 

London, 29 September 2021: Feedback plc (AIM: FDBK, "Feedback" or the
"Company"), the specialist clinical communication company, announces that it
has been awarded a place on a national procurement framework: The Provision
Artificial Intelligence (A.I), Imaging and Radiotherapy Equipment, Associated
Products and Diagnostic Imaging.

 

The Company has developed an AI module for the Bleepa communication platform
that enables third party AI tools to be deployed within the app by frontline
clinical users in order to assist with the diagnostic interpretation of
medical imaging studies such as X-rays, CT scans and MRIs. The AI module has
already been configured to deploy the AI tools of our commercial partners
Qure.ai and Axial 3D.

 

The Bleepa AI module will allow NHS Bleepa customers to engage with AI tools
of their choosing, knowing that they have a secure route of deployment right
into the hands of their clinicians. Bleepa's availability as a mobile platform
allows these AI tools to be deployed in any connected setting realising the
full benefits of AI driven point-of-care diagnostics in more places and in a
way that can't be recognised through traditional PACS based deployment, that
is largely confined to desktop PCs within hospitals.

 

Enabling on-the-go access to the latest AI diagnostic support tools is the
next evolution in the Company's mission to enable clinicians to make better
decisions faster from any location. The framework will allow NHS organisations
to buy the Bleepa AI solution as a platform for AI tool deployment, allowing
them to meaningfully engage with any number of AI tools knowing that there is
one common route for deployment into their clinical setting. The Company will
additionally charge the AI companies a deployment fee through the platform.

 

The framework is run by Shared Business Services (SBS) on behalf of NHS
organisations and enables NHS customers to directly procure equipment related
to AI imaging, including Bleepa's AI module. The framework has an estimated
overall value of up to £360m which lasts until 02/05/2025 and will be a key
resource to enable the NHS to engage with AI technology. Details of the
framework can be found at:

https://uk.eu-supply.com/ctm/Supplier/PublicTenders/ViewNotice/27445
(https://uk.eu-supply.com/ctm/Supplier/PublicTenders/ViewNotice/27445)

 

SBS describe the framework: "This is a framework agreement for the supply of
Artificial Intelligence software and platforms and also for the supply of
Medical Imaging and Radiotherapy equipment, associated products and Diagnostic
Imaging equipment. The framework aims to provide a simple, effective,
efficient and compliant route to market for the purchase/supply of a broad
range of medical imaging and radiology products and services, including
related artificial intelligence solutions. This will be for use by both NHS
Customers (and other public & private sector organisations) through means
of either direct call-off or further competition if required."

 

Dr Tom Oakley, CEO of Feedback, said: "This national framework is recognition
of the increasing interest in AI technology across the NHS and will enable NHS
customers to directly procure the Bleepa AI module as a vehicle for delivering
the ever-growing array of AI imaging tools available. Clinicians do not want
multiple apps on their devices and there is a clear role for a single platform
that facilitates the deployment of multiple AI tools. As a mobile first
solution, that additionally facilitates patient pathways and clinical case
discussion, Bleepa is the perfect deployment platform for AI tools, we can put
the latest AI technology literally into the hands of clinicians, through their
own devices, in any internet connected location, allowing truly on-the-go
access to the best available diagnostic support tools and point-of-care
deployment of AI technology in even more care settings."

 

 

-Ends-

 

Enquiries:

 

 Feedback plc                                    +44 (0)1954 718072

 Tom Oakley, CEO                                 IR@fbk.com (mailto:IR@fbk.com)

 Lindsay Melvin, CFO

 Panmure Gordon (UK) Limited (NOMAD and Broker)  +44 (0)20 7886 2500

 Emma Earl/Freddy Crossley (Corporate Finance)

 Rupert Dearden (Corporate Broking)

 Walbrook PR Ltd                                 Tel: 020 7933 8780 or feedbackplc@walbrookpr.com
                                                 (mailto:feedbackplc@walbrookpr.com)
 Paul McManus/Nick Rome/Nicholas Johnson         07980 541 893 or 07748 325 236 or 07884 664 686

 

Notes to Editors

 

Feedback plc (AIM: FDBK) is a pioneer of regulated clinical communication
products. Its core product, Bleepa, is a revolutionary medical imaging
communications app, providing an easy-to-use, high quality tool to enable
remote and secure communications between front-line clinicians and teams.
Importantly, it is the only CE marked medical imaging communications platform
on the NHSx clinical communications tools framework. Bleepa has unparalleled
functionality for everyday practice and can be accessed from any
internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will
provide increasing levels of visibility as the Company grows its customer
base. With a growing distribution base and technology in place, the focus is
on leveraging key relationships in order to drive sales both in the UK and
internationally to all forms of care providers. As a fully certified medical
device, Bleepa aims to disrupt the medical imaging communications market and,
importantly, increase the accuracy and speed of clinical review.

 

About NHS Shared Business Services

 

Established in 2005 by the Department of Health and Social Care (DHSC)
(https://www.gov.uk/government/organisations/department-of-health-and-social-care)
in a partnership with digital experts Sopra Steria
(https://www.soprasteria.co.uk/en) , its services are aimed at increasing
efficiency and quality, saving time and money, and supporting patient care.
The DHSC is transforming its current multiple delivery pathways
(https://www.sbs.nhs.uk/client-system-login) into one intelligent,
interconnected ecosystem that meets the ever-changing needs of the NHS in the
digital world. Offering a seamless experience with a single sign-on, its
modular solutions are aimed at enabling NHS organisations and suppliers to
access the services they need, when they need them including access to
suppliers or tendering for a multi-million pound project.

 

https://www.sbs.nhs.uk (https://www.sbs.nhs.uk)

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAEVLFLFKLZBBZ